Skip to main content
SpringerLink
Log in

Hemodialysis no reason to withhold everolimus

  • Letter to the Editor
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Pavel ME, Hainsworth JD, Baudin E et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378:2005–2012

    Article  PubMed  CAS  Google Scholar 

  2. Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523

    Article  PubMed  CAS  Google Scholar 

  3. Halfdanarson TR, Rubin J, Farnell MB et al (2008) Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer 15:409–427

    Article  PubMed  Google Scholar 

  4. Kirchner GI, Meier-Wiedenbach I, Manns MP (2004) Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 43:83–95

    Article  PubMed  CAS  Google Scholar 

  5. Deenen MJ, Klümpen HJ, Richel DJ et al (2012) Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies. Invest New Drugs 30:1557–1565

    Article  PubMed  CAS  Google Scholar 

  6. Thiery-Vuillemin A, Curtit E, Maurina T et al (2012) Hemodialysis does not affect everolimus pharmacokinetics: two cases of patients with metastatic renal cell cancer. Ann Oncol (Epub ahead of print)

  7. Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520–529

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, University Medical Center Groningen, P.O. Box 30001, Groningen, The Netherlands

    J. M. van Rooijen & E. G. E. de Vries

  2. University of Groningen, Groningen, The Netherlands

    J. M. van Rooijen & E. G. E. de Vries

Authors
  1. J. M. van Rooijen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. G. E. de Vries
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. M. van Rooijen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Rooijen, J.M., de Vries, E.G.E. Hemodialysis no reason to withhold everolimus. Cancer Chemother Pharmacol 71, 273–274 (2013). https://doi.org/10.1007/s00280-012-2021-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-012-2021-9

Keywords

Search

Navigation